A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2012
At a glance
- Drugs Sunitinib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov record.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.